@article{2038636a72f3467b83439b5a293b5d31,
title = "Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer",
author = "Crawford, {E. David} and Kane, {Christopher J.} and Harris, {Richard G.} and Bryce, {Alan H.} and Petrylak, {Daniel P.}",
note = "Funding Information: Janssen, Bayer and Pfizer. CJK declares that he declares stock ownership in Stratify Genomics. RGH and AHB report no conflicts of interest that might be relevant to the contents of this manuscript. DPP reports consultant fees from Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Incyte, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Roche, Seattle Genetics, Urogen and grant support from Advanced Accelerator Applications), Agensys Inc, *Astellas, AstraZeneca, *Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, *Eli Lilly, *Endocyte, Genentech, *Innocrin, MedImmune, Medivation, Merck, Mirati, *Novartis, Pfizer, *Progenics, Replimune, Roche, *Sanofi Aventis, Seattle Genetics",
year = "2021",
month = apr,
doi = "10.46883/ONC.2021.3504.0166",
language = "English (US)",
volume = "35",
pages = "166--168",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "4",
}